CNC

Centene Corporation 2024 Annual Report (10-K) Summary

Business Context and Reporting Period

This filing covers the fiscal year ended December 31, 2024. Centene Corporation is a leading healthcare enterprise providing managed care services primarily through government-sponsored programs (Medicaid, Medicare) and the Health Insurance Marketplace. The company operates in four segments: Medicaid, Medicare, Commercial, and Other. As of year-end 2024, Centene served 28.6 million members, representing a 4% increase from the prior year. The company is the largest Medicaid health insurer and Marketplace carrier in the U.S.

Key Financial Metrics

Note: Operating cash flow decreased significantly in 2024 primarily due to an increase in pharmacy receivables driven by rebate remittance timing associated with a new third-party Pharmacy Benefits Manager (PBM) transition.

Material Changes vs. Prior Period

• Membership Shifts: Total membership grew by 1.1 million. This was driven by a 50% increase in Medicare PDP membership and a 12% increase in Commercial Marketplace membership. Conversely, Medicaid membership declined due to post-pandemic eligibility redeterminations, and Medicare Advantage membership declined 13% due to strategic footprint reduction.
• Segment Performance:
  • Commercial: Revenues surged 36% and gross margin increased 52%, driven by Marketplace growth and favorable risk adjustment settlements.
  • Medicaid: Gross margin decreased 28% due to lower membership and higher medical acuity following redeterminations, despite rate increases.
  • Medicare: Gross margin decreased 9% due to lower Medicare Advantage revenue from Star rating impacts, partially offset by PDP growth.
  • Other: Revenues and gross margin declined 20% and 49% respectively, largely due to the divestiture of international businesses (Circle Health, Operose Health) and the conclusion of the TRICARE contract.
• Divestitures: Completed the sale of Circle Health Group (January 2024) and Collaborative Health Systems (October 2024), recognizing gains of $20 million and $17 million, respectively.
• Impairments: Total impairment charges dropped to $13 million in 2024 from $529 million in 2023, as major impairments related to Circle Health and Operose Health were recognized in the prior year.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• 2025 Expectations: The company expects to receive approximately $1.9 billion in net dividends from regulated subsidiaries and plans capital expenditures of roughly $700 million.
• Medicare Advantage: Management recorded a $92 million premium deficiency reserve for the 2025 plan year, anticipating operations at a loss driven primarily by Star ratings. The company is reducing its Medicare Advantage footprint to 32 states in 2025.
• Medicare Part D: The Inflation Reduction Act (IRA) changes effective in 2025 (elimination of coverage gap, $2,000 out-of-pocket cap) will shift cost-sharing responsibilities, increasing premiums and risk exposure for the company.
• Capital Allocation: The company repurchased $3.0 billion of stock in 2024. $2.2 billion remains available under the current repurchase program.

Key Risks & Contingencies:

• Regulatory & Political: Expiration of enhanced advance premium tax credits for Marketplace members in 2025; potential changes to Medicaid funding and eligibility; and CMS risk adjustment model revisions.
• Medical Cost Management: Inability to accurately estimate medical expenses or manage acuity, particularly in Medicaid post-redetermination.
• Contract Renewals: Risk of non-renewal or less favorable terms for government contracts, including Medicaid reprocurements in 2025/2026.
• Cybersecurity: Ongoing risks related to data breaches and third-party vendor failures (e.g., Change Healthcare incident in 2024).

Investor Verification Checklist

• Operating Cash Flow Volatility: Verify the timing of pharmacy rebate remittances and the impact of the new PBM contract on future cash flow stability.
• Medicare Advantage Deficiency: Review the assumptions behind the $92 million premium deficiency reserve for 2025 and the strategy for managing Star rating improvements.
• Medicaid Acuity Trends: Monitor the Health Benefits Ratio (HBR) in the Medicaid segment to ensure state rate adjustments are keeping pace with post-redetermination medical costs.
• Part D Risk Exposure: Assess the financial impact of the Inflation Reduction Act changes on the Medicare Part D segment in 2025.
• Dividend Restrictions: Confirm the availability of capital from regulated subsidiaries, noting that $9.1 billion of statutory capital is restricted from dividend payments.